Skip to main content
. 2022 Jan 20;11:811941. doi: 10.3389/fonc.2021.811941

Figure 5.

Figure 5

IL-6 fails to enhance TGF-β-induced SMAD-dependent EMT. (A) Phase-contrast images of TGF-β treated cells after 72 h of exposure compared to those of untreated control (scale bar: 100 μm). The encircled area represents morphologically distinct cells. (B) Transcript levels of N-Cad and vimentin after TGF-β treatment compared to those of untreated control. (C) Immunoblot showing expression of N-Cad and vimentin after TGF-β exposure for 72 h. (D) Immunoblot showing expression of SMAD2/3 after TGF-β treatment for 72 h; immunofluorescence image and relative fluorescence intensity of SMAD2 after TGF-β treatment (scale bar: 10 μm). The white arrow denotes SMAD2 protein. (E) Immunoblot showing SMAD3, N-Cad, and vimentin expression in cells treated with TGF-β or TGF-β plus SIS3 for 72 h (F) Immunoblot showing expression of N-Cad and vimentin after exposure to TGF-β or IL-6 or in combination for 72 h. **, *** and ns refers to p value significance of ≤0.01, ≤0.001 & not significant respectively.